Suppliers / Seven Star Pharmaceutical

Seven Star Pharmaceutical

Taiwan Updated 9 July 2026

Seven Star Pharmaceutical is an API manufacturer based in Taiwan. It holds 3 active US drug master files and 2 valid CEPs across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 21 April 2023 as NAI.

3
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 April 2023 NAI US FDA
  • 6 July 2018 VAI US FDA
  • 29 April 2016 VAI US FDA
  • 11 January 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
New Taipei City, Taiwan Not on file
Taiwan, Taiwan 3002769931

What they file, and where

Molecule Regulators Docs
Guaifenesin EDQM, US FDA 2
Acetylcysteine EDQM 1
Gadopentetate Dimeglumine US FDA 1
Methocarbamol US FDA 1

Also appears on these molecule pages

Acetylcysteine API Guaifenesin API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None

Comparing suppliers?

Choose your molecules and target markets. Seven Star Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 21 April 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability